Synthetic PCV2 Capsid Proteins for Vaccine Immunogenicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PCV2 vaccines face challenges with low viral titers, inability to maintain viruses in tissue cultures, and suboptimal expression and immunogenicity of natural capsid proteins, leading to inadequate immune protection against PCV2 infections in mammals.
Innovation Solution
Development of synthetic capsid proteins with improved properties, including specific amino acid sequences and fragments, which can be used alone or in combination with other immunogens to induce protective immunity, along with nucleic acids and vaccine compositions that include these proteins to enhance immune response and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If inactivated PCV2 vaccines are used, then immune protection is provided, but viral titers are low and viruses cannot be maintained in tissue cultures
Solution Approach 1:
The patent creates synthetic copies of the PCV2 capsid protein ORF2 sequence through recombinant DNA technology. The synthetic gene is inserted into expression vectors and produced in bacterial systems, generating large quantities of purified capsid protein that replicates the immunogenic properties of natural virus without requiring live viral cultures
Solution Approach 2:
The patent replaces the biological system of virus cultivation in tissue cultures with a biochemical system of recombinant protein expression in bacteria. This substitution eliminates the limitation of low viral titers and inability to maintain viruses in tissue cultures while producing sufficient immunogenic material for vaccination
2Reliability
If natural capsid proteins are used in Sub-Unit vaccines, then immunogenicity is achieved, but expression efficiency and immunogenicity are not optimal
Solution Approach 1:
The patent optimizes the capsid protein sequence by introducing specific amino acid substitutions that enhance both expression efficiency and immunogenicity. The modified sequence maintains essential immunogenic epitopes while improving protein stability, solubility, and antigenic properties for better vaccine performance
Solution Approach 2:
The patent creates chimeric capsid proteins by fusing the PCV2 ORF2 sequence with carrier proteins or adjuvant molecules. These composite structures enhance immunogenicity by combining the viral antigen with immunostimulatory elements, providing stronger and more durable immune protection
3Reliability
If current PCV2 vaccines are used, then some immune protection is provided, but the level of immune protection is inadequate
Solution Approach 1:
The patent extracts only the essential immunogenic portion of the PCV2 virus - the ORF2 capsid protein sequence - and uses this purified component as the vaccine antigen. This extraction approach provides adequate immune protection by focusing on the most immunogenic elements while simplifying the overall vaccine composition and production
Data Source
AI summary
The present invention relates to synthetic proteins and the uses thereof. More particularly, the invention relates to synthetic Circovirus type capsid proteins with improved properties. These proteins, or the coding nucleic acids, are useful e.g., to generate antibodies, immunogen compositions, or vaccines. The invention further relates to methods for treating and/or preventing PCV2-associated diseases in mammals using said proteins, nucleic acids or compositions. The invention also relates to compositions and methods for detecting PCV2 in a sample, using the above proteins, nucleic acids, or antibodies.